Shopping Cart
Your Cart is Empty
Quantity:
Subtotal
Taxes
Shipping
Total
There was an error with PayPalClick here to try again

News from CaSfA's Director
News from CaSfA's Director
Blog
USPSTF's Recommendations for PSA Testing
Posted on April 18, 2017 at 1:17 PM |
The
US Preventive Services Task Force recently released a draft statement with updated
advice for the use of Prostate Specific Antigen (PSA) in screening for prostate
cancer. They will be accepting public
feedback regarding their recommendations until May 8, 2017, after which time a
final recommendation will be released. Back
in 2012, the USPSTF unequivocally told doctors to discourage patients from
getting PSA testing. They stated that
the risks of false positives and overtreatment outweighed the benefits. But after much debate, the USPSTF has backed
off that advice. Here
is the upshot of their updated recommendations from https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementDraft/prostate-cancer-screening1 ▪ PSA tests for men age 70 and
older and men under age 55 are still discouraged ▪ For men between 55 and 69, the
panel is punting the decision to doctors. “The decision about whether to be screened for
prostate cancer should be an individual one.
Screening offers a small potential benefit of reducing the chance of dying of
prostate cancer. However, many men
will experience potential harms of screening, including false-positive results that require
additional testing and possible prostate biopsy; overdiagnosis and overtreatment; and treatment
complications, such as incontinence and impotence. The USPSTF recommends individualized decision making about
screening for prostate cancer after
discussion with a clinician, so that each man has an opportunity to understand the potential benefits and
harms of screening and to incorporate his values and preferences into his decision.” ▪ The task force backed down on
its earlier advice in light of new evidence. Back in 2012, the best evidence suggested that for
every 1,000 men screened, 0.8 prostate cancer deaths would be prevented in the
next 10 to 15 years. But a longer look at the participants in prostate cancer
studies has raised that to 1.3 deaths prevented in the same time frame. Additionally, studies have since reported
that screening 1,000 men ages 55 to 69 years may prevent approximately 3 men
from developing metastatic prostate cancer. ▪ The panel also took into
consideration that how men seek treatment has shifted. More men now who receive cancer
diagnoses are opting for active surveillance — watching their cancer closely —
rather than treatment. That lessens the potential harms, such as impotence and
incontinence after surgery; compared to the last time the task force evaluated
the screenings. More detailed information is in CaSfA's April 18, 2017 newsletter. Join CaSfA to receive our newsletters!! |
Categories: prostate cancer
Post a Comment
Oops!
The words you entered did not match the given text. Please try again.
0 Comments
Loading...
/
Oops!
Oops, you forgot something.